In the last 3 months. On the site you’ll find the news from the last 3 months. The older ones only have the title and a link, in file by topicsIt’s a support website for people with multiple myeloma. It aims to keep things simple and clear. MielomaAI As you may find.
Collected from Portuguese newspapers, Google News (PT, EN, ES, FR) and associations and scientific societies. They are on the website 206 news: only from the last 3 months. The older ones are only shown with the title and link, in file by topicsAnd research and the MielomaAI continuam a encontrá-las. Abra sempre a notícia original e fale com o seu médico antes de tirar conclusões sobre o seu caso. Última recolha: 17 nov 2026, 21:48.
Tuesday, November 17
Dr Frigault on Anito-Cel’s Potential to Reduce Post CAR T BurdenTargeted Onc (EUA) · 18:07 TratamentosEUAMatthew J. Frigault, MD, MS, discusses how the novel myeloma CAR T-cell therapy anitocabtagene autoleucel could reduce the need for extended surveillance for delayed toxicities.
Monday, 16/11
Ben Derman։ Top 10 Myeloma Abstracts to Be Presented at ASH 2026Oncodaily · 18:05 InvestigaçãoBen Derman։ Top 10 Myeloma Abstracts to Be Presented at ASH 2026 / ASCO, ASH 2026, Ben Derman, cancer, CAR-T, DARA, Daratumumab, Lenalidomide, Mount Sinai,
MM’s Vulnerability to CAR T Was a Happy Surprise: Nikhil C. Munshi, MDThe American Journal of Managed Care® (AJMC®) (EUA) · 00:11 TratamentosEUAA single chimeric antigen receptor (CAR) T-cell infusion can clear heavily pretreated myeloma in 2 weeks, highlighting the immune system’s adaptability.
Friday, November 13
Seminar in Coimbra brings together patients and specialists to discuss multiple myeloma and the role of CAR-T cellsHealthNews (Portugal) · 07:08 Patients and associationsPortugalPT
Wednesday, 11/11
- Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D CandidateGlobeNewswire (Internacional) · 13:53 TratamentosInternacional
-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates -Lead BCMA/GPRC5D...
Tuesday, November 3rd
Early Relapsed Myeloma: No Efficacy Hierarchy Established Between CAR T Cells and Bispecific AntibodiesOncodaily (Reino Unido) · 08:00 TratamentosReino UnidoEarly Relapsed Myeloma: No Efficacy Hierarchy Established Between CAR T Cells and Bispecific Antibodies / Bispecific antibodies, cancer, CAR-T, Headlines,
High-Risk Multiple Myeloma Linked to Earlier CAR-T Cell FailureEMJ (Reino Unido) · 08:00 TratamentosReino UnidoHigh-risk multiple myeloma features were associated distinct patterns of treatment failure after cilta-cel.
Thursday, October 29th
Starton Therapeutics Signs Clinical Trial Agreement with the Stanford School of Medicine to Evaluate STAR-LLD in Combination with Novel CAR-T Therapy for Multiple MyelomaBusiness Wire (Internacional) · 07:00 TratamentosInternacional
Quinta, 22/10
Bharat Biotech's Nucelion, VeGen Bio Target 2028 Launch For India's First Dual-Target CAR-T Therapy For MyelomaETV Bharat (China) · 07:00 TratamentosChinaThe Strategic alliance advances VL-2511, a first-in-class dual BCMA/CD19 autologous CAR-T therapy for multiple myeloma, towards a first-in-India Phase 1/2 trial and targeted 2028 commercialisation.
Quarta, 21/10
New CAR-T therapy for multiple myeloma to enter India trials soonThe Federal (China) · 07:00 TratamentosChinaBharat Biotech arm Nucelion and VeGen Bio partner to develop dual-target CAR-T cell therapy, aiming for clinical trials and potential 2028 commercialisation
VeGen Bio teams up with Nucelion Therapeutics to advance dual-target Myeloma CAR-Tpharma.economictimes.indiatimes.com (China) · 07:00 TratamentosChinaVL-2511 is a first-in-class dual autologous CAR-T therapy for multiple myeloma which simultaneously targets BCMA and CD19. Under the agreement, the contract researcher will advance the drug in a Phase 1/2 trial in India
Indian Biotechs Collaborate on Locally Manufactured Multiple Myeloma CAR TGenomeWeb (China) · 07:00 Acesso e saúde públicaChinaThe pair are looking to lower costs and improve access to the China-developed dual-targeting therapy.
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed MyelomaTargeted Onc (EUA) · 07:00 Acesso e saúde públicaEUADuring a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
Segunda, 19/10
NCCN Guidelines Position CAR T Cells in Early Relapsed Multiple MyelomaCancerNetwork (EUA) · 07:00 Acesso e saúde públicaEUAMatthew J. Frigault, MD, and Adam D. Cohen, MD, outline how updated NCCN guidelines position CAR T-cell therapy in early relapsed multiple myeloma.
Quinta, 08/10
Zenbexus PFS Data Suggest Utility In Community Treatment Of Multiple MyelomaScrip (China) · 07:00 TratamentosChinaFollowing approval in August, Bristol Myers Squibb reports Phase III PFS data that may make the oral CELMoD an ideal option for community care centers less suited to administering CAR-T and bispecific antibodies.
Terça, 06/10
Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myelomaNature · 07:00 TratamentosExtended follow-up of four patients with multiple myeloma treated with in vivo BCMA CAR-T cells showed limited duration of response in three patients, while one patient had sustained response to 15 months.
Segunda, 28/09
IASO Bio’s in vivo BCMA CAR-T posts 90% response rate in first human studyAllSci (China) · 07:00 InvestigaçãoChina
Sexta, 25/09
CAR-T manufacturing & delivery for multiple myeloma patientsJohnson & Johnson (Internacional) · 07:00 Doentes e associaçõesInternacional
Quarta, 23/09
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent MyelomaThe New England Journal of Medicine (EUA) · 21:52 InvestigaçãoEUA
Terça, 08/09
Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpointFierce Biotech (EUA) · 07:00 InvestigaçãoEUA
Notícias com mais de 90 dias: só o título e o link para a fonte.
Pay attention to old news. Marked as. about 1 year 2 years 5 years 10 years You may also want to check that the information is still up to date: treatments, approvals and prices change quickly. Always confirm with your hematology team.
Access and public health
- BH Hospital offers CAR-T cell treatment for patients with multiple myeloma ↗ about 1 year · City Connect · 11/09/2025
- A multiple myeloma patient treated at the 12 of October Hospital with the first commercially available CAR-T in Spain is disease-free seven months later ↗ about 1 year · Madrid Community | · 24/02/2025
- FDA lifts partial suspension of Arcellx’s CAR-T CART-ddBCMA trial in multiple myeloma ↗ 3 years · CGTLive® · 15/08/2023
- Approval of Carvykti becomes the second CAR-T therapy for multiple myeloma ↗ 4 years ago · National Cancer Institute (.gov) · 30/03/2022
- FDA approves BCMA-targeted CAR-T therapy for multiple myeloma ↗ 5 years · National Cancer Institute (.gov) · April 14, 2021
Patients and associations
- The CAR-T from Clínic-IDIBAPS for multiple myeloma is effective in patients with rising disease ↗ 3 years · Clínic Barcelona · 04/07/2023
- Einstein uses CAR-T cells in patients with multiple myeloma ↗ 3 years · Medicine Inc. · 13/12/2022
Research
- First results from the first in vivo CAR-T study in multiple myeloma ↗ · The ASCO Post · February 25, 2026
- Phase 1 trial of the CAR-T BCMA NEX-T® CC-98633/BMS-986354 therapy in patients with multiple myeloma who have been previously exposed to three classes of drugs ↗ about 1 year · Nature · 05/02/2025
Treatments
- Waiting for CAR-T cells. Gualter's journey to silence multiple myeloma ↗ · Public · 04/07/2026
- Clinic-IDIBAPS optimizes CAR-T academic against multiple myeloma to treat relapses. · Hospital Clínic Barcelona · 20/03/2026
- Gilead-Arcellx Agreement: Up to $7.8 Billion for Anito CAR-T Cell Therapy in Multiple Myeloma · Oncodaily · 26/02/2026
- Kelonia Therapeutics announces the FDA approval of the Investigational New Drug (IND) application for KLN-1010, an in vivo CAR-T therapy for relapsed or refractory multiple myeloma. ↗ · Business Wire · 07/01/2026
- ASH 2025: ASH 2025: Arcellx and Gilead’s anti-CD38 CAR-T cell therapy challenges the myeloma market in relapse/refractory disease ↗ · Clinical Trials Arena · 12/09/2025
- A new experimental CAR-T therapy shows high efficacy in multiple myeloma ↗ about 1 year · Clínic Barcelona · 19/09/2025
- Mater Dei will now offer CAR-T treatment for multiple myeloma ↗ about 1 year · Medicine Inc. · 05/09/2025
- Mater Dei innovates in the treatment of multiple myeloma with CAR-T therapy. about 1 year · Health Business · 04/09/2025
- ASH: New data from Gilead and Arcellx strengthen its CAR-T approach versus Carvykti in advanced multiple myeloma ↗ 2 years · Fierce Biotech · 11/05/2024
- Carvykti, from J&J and Legend, shows that CAR-T can prolong life in multiple myeloma ↗ 2 years · Fierce Pharma · 02/07/2024
- ASCO: After the shine of CAR-T, GSK strengthens the arguments for Blenrep in multiple myeloma ↗ 2 years · Fierce Pharma · 02/06/2024
- New immunotherapy against multiple myeloma shows greater efficacy in the laboratory than CAR-T, which is already in use ↗ 2 years · National Centre for Oncology Research - NCIO · 14/02/2024
- Researchers find treatment options for patients whose cancer returns after CAR-T ↗ 4 years ago · ScienceDaily — Multiple Myeloma · 04/11/2022
- Treating multiple myeloma with CAR-T cells, an innovative immunotherapy ↗ 7 years · University Hospital of Poitiers Website · 18/10/2019
